IL23A and inflammatory bowel disease: TNF antibodies, IL-12/IL-23p40 antibody (ustekinumab), selective IL-23p19 antibodies (e.g., risankizumab, guselkumab, mirikizumab), and JAK inhibitors (e.g., tofacitinib, upadacitinib), which have demonstrated efficacy in IBD, may also impact myeloid cells [136].